Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07391761

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

The purpose of this study is to evaluate:

* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Refractory Multiple Myeloma (RRMM) Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kaohsiung Chang Gung Memorial Hospital, Kachsiung, Taiwan

Loading trial locations.

About this study

This study is seeking participants who:

  • have relapsed or refractory multiple myeloma (RRMM),
  • have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
  • are 18 years or older.

Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients age ≥ 18 years at the initiation of elranatamab
  • Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
  • Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

Exclusion criteria

Patients who participated in any prior clinical trials using elranatamab.

Treatment and study plan

Non intervention

Drug

Non intervention

Primary outcomes

  1. rwTTR (real-world time to response)

    Time frame: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

    Time from index date to the first documented real-world response.

  2. rwORR (real-world overall response rate)

    Time frame: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

    Proportion of patients achieving real-world overall response at predefined assessment time points.

  3. rwDOR (real-world duration of response）

    Time frame: From first response until 18 months

    Time from the first documented real-world response to real-world disease progression, death, or end of study.

  4. rwPFS (real-world progression-free survival)

    Time frame: From initiation of elranatamab treatment (index date) until 18 months

    Time from index date to the first documented real-world disease progression or death.

  5. rwOS (real world overall survival)

    Time frame: From initiation of elranatamab treatment (index date) until 18 months

    Time from index date to death from any cause.

  6. rwTTNT (real world time to next treatment)

    Time frame: From initiation of elranatamab treatment (index date) until 18 months

    Time from index date to initiation of the next line of anti-myeloma therapy or end of study.

Secondary outcomes

  1. Demographic: Age

    Time frame: At baseline

    Age (measured in years)

  2. Demographic: Sex

    Time frame: From MM diagnosis until index date, and from index date until 18 months

    sex/gender (male/female)

  3. Anthropometric Measures

    Time frame: At baseline

    Height (in cm), weight (in kg), BMI (kg/m²),

  4. ECOG Performance Status

    Time frame: At baseline

    Number and proportion of patients in each ECOG PS category (0-5)

  5. Myeloma-related Clinical Characteristics

    Time frame: At baseline

    Baseline disease characteristics including myeloma type (IgG, non-IgG, light-chain, non-secretory), bone marrow plasma cell %, presence of EMD, ECOG status, CRAB symptoms, ISS/R-ISS stage, MGUS, SMM, and cytogenetic risk.

  6. Laboratory Characteristics

    Time frame: At baseline

    Baseline laboratory result of creatinine clearance (CrCl) categories (stages 1-5 or <30/≥30 mL/min)

  7. Prior Treatment History

    Time frame: At baseline

    Number and proportion of patients with prior ASCT, prior anti-MM therapies

  8. Time from Diagnosis and Line of Elranatamab Treatment

    Time frame: From the index date (initiation of elranatamab treatment) up to 18 months

    Time from MM diagnosis to elranatamab initiation.

  9. Elranatamab Discontinuation and Treatment Modifications

    Time frame: From the index date (initiation of elranatamab treatment) up to 18 months

    Number and proportion of patients with treatment discontinuation (and reasons), dosing or schedule modifications (excluding step-up), and switches from QW to Q2W after 6 cycles.

  10. Subsequent Treatments After Progression

    Time frame: From the index date (initiation of elranatamab treatment) up to 18 months

    Number and proportion of patients receiving subsequent treatments following first progression or discontinuation of elranatamab.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 6, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.